关注息肉状脉络膜病变的治疗

Rethinking about the treatment of polypoidal choroidal vasculopathy

息肉状脉络膜病变(PCV)目前被归类为新生血管性年龄相关性黄斑病变(nAMD)的一个亚型,但PCV的临床表现和治疗预后与nAMD有显著差异。鉴于PCV在亚洲人群中有较高的发病率,眼底专家推行了多项随机对照临床试验用于研究针对PCV的有效和经济适用的治疗方案,并为PCV患者的诊治提供1级循证医学证据。本文从PCV治疗中存在的一些问题入手进行探讨,希望对未来治疗该疾病的方向引发一些思考。

Polypoidal Choroidal Vasculopathy(PCV)is now categorized as a subtype of neovascular Age-related Macular Degeneration(nAMD),though the ocular manifestation and prognosis of PCV patients are quite distinct from nAMD.Due to its high prevalence in Asian population,retina specialists have implemented multiple randomized control trials(RCT)in recent years,aiming at providing grade 1 clinical evidence for current therapies and exploring efficient and affordable regimens for long-term management of PCV.Here we summarised current problems existed in available RCTs and prognostic biomarkers,and presented our thoughts based on previous clinical experiences which may be helpful for clinical management of PCV.